DAY 5: Tuesday, June 7
Welcome to the last of the 2022 Today@ADA – a round-up of my picks from Day 5 at the American Diabetes Association’s 82nd Scientific Sessions. Each day of the congress I have brought you a daily interview with one of our key speakers, and a presentation of my top picks from everything that went live – with my personal takes and commentary. You can revisit anything you missed and want to catch-up with in full in the on-demand sessions.
The last in our interview series is with Richard David Leslie of the Blizard Institute in the UK. His talk early on the morning of Day 5 was on whether diabetes should be rethought. Watch the interview to learn about the key ideas behind this.The last day at the congress kept delivering incredible talks from experts in the field of diabetes. The first presentation I have summarized is from the symposium on the future of diabetes, and the potential of dual incretin therapy, where the legendary Julio Rosenstock presented on whether the achievement of normoglycemia could become a treatment goal for patients with type 2 diabetes – a feat that would have been unthinkable just a few years ago.
And my second pick for Day 5 is Auriel Willette from Iowa State University. In a session on dementia and diabetes, Auriel delivered a fascinating talk on the impact of obesity and type 2 diabetes on brain structure and function.
We hope you have enjoyed the Today@ADA resources. There is an official Highlights program in development, which will provide a selection of high-quality summaries, key posters and downloads. Access is free, so do share the information with your colleagues who may not have been able to attend the Scientific Sessions.
As always, we welcome your feedback and comments on what you liked about the Today@ADA offering, and what you would like to see next year.
All that remains for me to say is – thank you for joining us, whether in person here in New Orleans, or via the remote portal.
Dana Dabelea, MD, PhD
ADA 2022 Highlights Editor
Denver, CO, USA